The Relationship Between PDE-5 Inhibitors and NAION

Update Item Information
Identifier 20150223_nanos_journalclub1_02-1
Title The Relationship Between PDE-5 Inhibitors and NAION
Creator Howard D. Pomeranz, MD
Affiliation North Shore Long Island Jewish Health System and Hofstra North Shore LIJ School of Medicine, Great Neck, NY
Subject Erectile Dysfunction Drug; Non-Arteritic Anterior Ischemic Optic Neuropathy; Phosphodiesterase 5 (PDE-5) Inhibitor; Pfizer; Sildenafil
History Sildenafil was first synthesized by pharmaceutical chemists working at Pfizer. It was initially studied for use in hypertension and angina. Phase I clinical trials suggested that the drug had little effect on angina but could induce penile erection. Sildenafil (Viagra®) was patented in 1996 and approved by the FDA for use in erectile dysfunction (ED) in March, 1998. Vardenafil (Levitra®) was approved by the FDA for treatment of erectile dysfunction in August, 2003 and tadalafil (Cialis®) in November, 2003. Avanafil (Stendra®) was approved in April, 2012. Udenafil (Zydena) is not FDA approved for sale in the United States, but is available in Korea, Russia and the Philippines.
Date 2015-02
Language eng
Format video/mp4
Type Image/MovingImage
Relation is Part of NANOS Annual Meeting Journal Club, 2015
Collection Neuro-Ophthalmology Virtual Education Library - Walsh Session Annual Meeting Archives https://novel.utah.edu/Walsh/index3.html
Publisher Spencer S. Eccles Health Sciences Library, University of Utah
Holding Institution Spencer S. Eccles Health Sciences Library, University of Utah, 10 N 1900 E SLC, UT 84112-6233
Rights Management Copyright 2015. For further information regarding the rights to this collection, please visit: https://NOVEL.utah.edu/about/copyright
ARK ark:/87278/s628355b
Setname ehsl_novel_fbw
ID 179290
Reference URL https://collections.lib.utah.edu/ark:/87278/s628355b
Back to Search Results